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ABSTRACT
Background: The literature on antipsychotic medication in psychosis lack systematization of the
empirical knowledge base on patients’ subjective experiences of using antipsychotic drugs. Such inves-
tigations are pivotal to inform large-scale trials with clinically relevant hypotheses and to illuminate
clinical implications for different sub-groups of individuals.
Aims: To re-analyze and summarize existing qualitative research literature on patient perspectives of
using antipsychotic medication.
Method: A systematic literature search was performed in September 2018 (Protocol registration no.
CRD42017074394). Using an existing framework of meta-analyzing qualitative research, full text evalu-
ation was conducted for 41 articles. Thirty-two articles were included for the final synthesis.
Results: Four meta-themes were identified: (1) short-term benefits; (2) adverse effects and coping
processes; (3) surrender and autonomy; (4) long-term compromise of functional recovery.
Conclusions: While largely positive about acute and short-term use, patients are more skeptical about
using antipsychotic drugs in the longer term. The latter specifically relates to processes of functional
and social recovery. The clinical conversations about antipsychotic medication need to include evalua-
tions of contexts of patient experience level, patient autonomy processes, patient values and risk pref-
erences, and patient knowledge and knowledge needs in addition to assessing the severity of
symptoms of psychosis.
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Standardized clinical treatment guidelines recommend that
individuals with psychosis be treated with antipsychotic
medication in the acute phase as well as throughout the
protracted phases of maintenance and recovery (APA, 2006;
NICE, 2014). Antipsychotic medication has unequivocally
proven effective in acute and short-term treatment (Bola,
Kao, & Soydan, 2012; Lally et al., 2017; Leucht et al., 2017;
Mackin & Thomas, 2011). Over the longer term, there are
significant challenges related to this type of treatment.
First, a sizable share of those remitting after a first epi-
sode psychosis may be able to achieve a good long-term
outcome with a very low dose or without antipsychotic
drugs at all. Robust predictors for the early identification of
these patients are still lacking, which may result in excessive
use of antipsychotic medicine (Harrow, Jobe, Faull, & Yang,
2017; Moilanen et al., 2013; Murray et al., 2016; Wunderink,
Nieboer, Wiersma, Sytema, & Nienhuis, 2013). Second,
severe side effects, particularly associated with long-term
use, include grey matter volume decrease and lateral ven-
tricular volume increase (Fusar-Poli et al., 2013; Moncrieff
& Leo, 2010), diabetes (Rajkumar et al., 2017), metabolic
syndrome (Vancampfort et al., 2015), and reduced subject-
ive quality of life and functioning (Wunderink et al., 2013;
Wykes et al., 2017). Third, shared decision-making has
become a stated priority in medical treatment in an attempt
to reduce the use of compulsory treatment and increase sub-
jective empowerment and adherence to treatments that are
actively chosen (Leng, Clark, Brian, & Partridge, 2017).
Hence, shared decision-making is a central part of the
recovery paradigm (Alguera-Lara, Dowsey, Ride, Kinder, &
Castle, 2017). This perspective has emerged resulting from a
growing body of evidence showing a gap between the real-
ities of those who use, refuse, or are forced to take anti-
psychotic medication and professionals and researchers
(Faulkner, 2015; Moncrieff, 2013). Nevertheless, and despite
non-adherence to treatment recommendations continuing to
be considered a sizeable public health problem (Kane,
Kishimoto, & Correll, 2013), few studies have investigated
the effects of shared decision-making in mental healthcare
settings (Boychuk, Lysaght, & Stuart, 2018; Schauer, Everett,
del Vecchio, & Anderson, 2007; Slade, 2017; Stovell,
Morrison, Panayiotou, & Hutton, 2016).
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Large scale, prospective long-term, double-blind, con-
trolled studies using clearly defined samples in terms of ill-
ness type, severity, and duration evaluating treatment effect
are lacking (Sohler et al., 2016). These types of studies are
essential to reveal how antipsychotic treatment affects crit-
ical functioning throughout the course of illness (Rhee,
Mohamed, & Rosenheck, 2018; Zipursky & Agid, 2015).
Also, meta-analyses of qualitative studies are needed to sys-
tematically describe and summarize the growing empirical
qualitative knowledge base on service users’ subjective per-
spectives on using antipsychotic drugs. Such studies are
essential to inform large-scale trials with clinically relevant
hypotheses, as well as to illuminate clinical implications for
different sub-groups of individuals.
Objective
The aim of this study is re-analyze and summarize the exist-
ing qualitative research literature on patient perspectives on
using antipsychotic drugs.
Method
Qualitative meta-analyses offer secondary analyses of multiple
primary studies addressing the same research question
(Finfgeld, 2003; Timulak, 2014). To ensure comprehensive
and transparent reporting of methods and results, this quali-
tative meta-analysis was performed in three steps: first, the
PRISMA guidelines (Hutton et al., 2015; Moher et al., 2015)
were applied for search strategy and data extraction. Second,
the Critical Appraisal Skills Programme (CASP) checklist
(CASP, 2013) was used for quality appraisal and final study
inclusion. Third, data analysis followed an established frame-
work for meta-analyzing qualitative studies (Thomas &
Harden, 2008; Timulak, 2009). The protocol was registered at
PROSPERO International prospective register of systematic
reviews in August 2017 (Registration no. CRD42017074394).
Search strategy
A systematic literature search was performed using the fol-
lowing electronic databases: PsycINFO, CINAHL, Embase,
Medline, Web of Science, SCOPUS, and Cochrane Library.
Search terms were developed to identify qualitative research
exploring experiences of taking anti-psychotic medications
from a first-person perspective, and final search terms were
adapted accordingly to fit the different databases’ search
engines. In addition to relevant subject headings, all searches
included the following terms: (antipsychotic or neuro-
leptic or aripiprazole or clozapine or molindone or niala-
mide or olanzapine or quetiapine or reserpine or risperdone
or sulpiride or tetrabenazine or acepromazine or azaperone
or benperidol or butaclamol or chlorpromazine or chlorpro-
thixene or clopenthixol or clozapine or droperidol or etazo-
late or flupenthixol or fluphenazine or fluspirilene or
haloperidol or loxapine or lurasidone hydrochloride or mes-
oridazine or methiothepin or methotrimeprazine
or molindone or ondansetron or paliperidone palmitate or
penfluridol or perazine or perphenazine or pimozide or
prochlorperazine or promazine or quetiapine fumarate or
raclopride or remoxipride or ritanserin or spiperone or sul-
piride or thioridazine or thiothixene or tiapride hydrochlor-
ide or trifluoperazine or trifluperidol or triflupromazin)
AND (psychosis or psychoses or psychotic or schizo or
delusio or hallucinat or hallucinos or paranoi) AND
(focus group or qualitative research or qualitative study or
qualitative studies or qualitative method or phenomenolog
or interpretive or interpretative or hermeneutic or “first
person” or "self-report" or narrativ or “grounded theory”
or “field stud”). The search query was approved by an
information scientist and was limited to title, abstract, and
key words. In addition, a manual literature search was per-
formed using reference lists of reviews and meta-analyses.
No time restriction period was applied for publication inclu-
sion. The final search was performed 25 September 2018.
Inclusion criteria
The included articles were required to meet all of the fol-
lowing criteria:
Empirical study published in English language in peer
reviewed journals.
Derived from a sample meeting criteria (DSM/ICD) for a
psychotic disorder.
Using qualitative methods for both data collection and data
analysis (minimum score of 1 (satisfactory quality) on overall
study rating. See Table 1, right column).
Explicitly explore first-person perspectives of taking
antipsychotic medication, including both first- and second-
generation drugs.
Data material and data analysis
All potential studies were exported into a reference citation
manager and duplications were removed. Two independent
reviewers (M. V. and K. O. L.) separately performed the
screening of titles and abstracts. Based on this screening they
suggested a list of articles eligible for full text review (N =
41). Next, a consensus meeting was arranged with J. B., K. O.
L., C. M., and M. V. Here, eligible articles were critically
assessed based on full-text review using a two-step procedure;
(1) a systematic quality appraisal framework (CASP, 2013),
including a separate quality evaluation of each of the eligible
studies according to the 10 CASP criteria (see Table 1 for
details), and (2) an established framework for meta-analyzing
qualitative data (Thomas & Harden, 2008; Timulak, 2009)
and consensual qualitative research (Hill, Thompson, &
Williams, 1997) using the following steps:
J. B., K. O. L., M. V., A. H., and C. M. read all papers
independently and made preliminary analytic notes establishing
tentative and characteristic themes. A theme is a construct “that
captures something significant about the data in relation to the
research question and represent some level of patterned response
or meaning within the data set” (Thomas & Harden, 2008).
Themes were secondary analysis of primary study reported
categories or themes. We aimed to develop nuanced and in-
depth knowledge about the phenomenon of focus by analyzing
both commonalities as well as variations in the primary data.
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A meeting with J. B., K. O. L., M. V., and C. M. was held to
compare preliminary analyses and decide structure of meta-
themes, and development of a model of interrelated processes
between meta-themes.
To ensure representativeness and overall relevance across the
data material, J. B. and C. M. re-read primary articles, searched
for illustrative quotes, and started the write-up of the findings.
Last, the tentative model of findings, with illustrative quotes,
was sent to A. H. who served as a critical auditor assessing the
interpretations made through our descriptions of the central
organizing concepts.
Next, the consensus evaluation of the 41 eligible studies
was sent to an auditor (A. H.) for critical evaluation of the
data extraction process. The auditor carried out the same 2-
step analytic process as described above. L. D. had a general
role, including interlinking the study findings to the litera-
ture and discussing their clinical implications.
Methodological integrity and validity checks
Performing methodological and validity checks is recom-
mended practice when conducting qualitative meta-analyses
(Timulak, 2009), and such procedures ensure that the inter-
pretation of data is shared by multiple researchers (Levitt,
Pomerville, & Surace, 2016). The following methodological
integrity and validity checks were performed in order to
enhance the quality of our analysis:
Inter-rater reliability measures (Kappa) between K. O. L. and
M. V. while screening and selecting studies were performed to
ensure that inclusion criteria were clearly stated and that papers
were assessed equally.
Consensus processes were chosen to foster multiple
interpretations and perspectives of the data. The overall aim of
consensual research is to improve decision quality through
valuing diversity in viewpoints, equal involvement and mutual
respect among the involved researchers (Hill et al., 2005) by
facilitating an open dialogue throughout the screening, analysis
and write-up process. All researchers read through the data
papers and independently established a tentative framework of
results prior to the analysis seminar to stimulate multiple
perspectives and mutual involvement.
A critical auditor was selected to review and provide detailed
feedback on each stage of the analysis and writing process. In
accordance with Hill (2012), the critical auditor’s role was to
check whether important material was represented in the meta-
themes and that the wording captured the essence of data
material and the validity of the structure of findings.
Keeping the first-person account in mind while interpreting the
data was sought to accommodate the voice of the patient.
Practically, this meant that we attended carefully to and prioritized
patient quotes while analyzing the data, and we also searched for
illustrative quotes to inform the writing of the findings.
Results
Search results
The electronic search returned 10,514 articles. A hand
search of reference lists of reviews and meta-analyses
returned a further three articles. After duplicates were
removed, there were left 6392 articles. Six thousand three
hundred forty-nine articles were excluded after a review of
title and abstract, yielding them outside inclusion criteria.
Full text evaluation was conducted for 43 articles, of which
32 articles met the inclusion criteria and were included for
the final analysis. The main reasons for exclusion were the
following: the study sample did not consist of participants
meeting criteria (DSM/ICD) for a psychotic disorder or
diagnosis of some/all participants was unclear or not stated,
unclear, or not stated pharmacological treatment, did not
explore first-person perspectives of taking anti-psychotic
medication, or not involving qualitative analysis of qualita-
tive data (see Figure 1 for details on the review process).
Inter-rater reliability for inclusion of articles was satisfac-
tory-high (Kappa = 0.76).
Quality appraisal and study characteristics
Of the included studies (CASP-based assessment, see Table
1), 19 studies achieved satisfactory and 11 studies excellent
total score. Generally, contextual, reflexive and ethical issues
achieved lowest scores. Across articles, a total of 519 partici-
pants were included and the mean number of participants
was 16.7 (SD = 7). Participants’ age ranged from 13 to 70
years and mostly came from Anglo-American cultures (see
Supplementary material, Sample and context). Mean age
was not possible to calculate as several studies only included
age range. Approximately 42% were female participants. A
precise number was not possible to estimate due to missing
reports of gender in some studies. While all included papers
comprised experiences of taking some type of antipsychotic
medication, 20 studies did not specify drug type. Five stud-
ies applied second generation and five studies used com-
bined first- and second-generation drugs. The studies
originated from a variety of countries, including Australia
(4), Brazil (1), Canada (3), China (1), Iran (1), Ireland (1),
Norway (4), Sweden (2), Taiwan (1), United Kingdom (12),
Records identified through 
database searching
(n = 10514)
Additional records identified 
through other sources
(n = 3)
Records after duplicates removed
(n = 6392)
Records screened by title and 
abstract
(n = 6392)
Full-text articles assessed for 
eligibility
(n = 43)




(n = 11) 
Non-psychotic medications








Records excluded based on 
title and abstract
(n = 6349) 
Figure 1. Flow diagram of the reviewing process according to PRISMA
(adapted from Moher, Liberati, Tetzlaff, & Altman, 2009).
























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4 J. BJORNESTAD ET AL.
and United States (2). A descriptive overview of included
studies is presented in Supplementary material.
Meta themes
Four meta-themes resulted from the meta-analytic proce-
dures, in which we look for both thematic divergence and
convergence in the results sections of the included papers.
The meta-themes comprise the first-person experiential
domains of (a) short-term benefits, (b) adverse effects and
coping processes, (c) surrender and autonomy, and (d) the
long-term compromise of functional recovery. The degree of
representativeness held by the different meta-themes could
be indicated by how many of the included papers contribute
to the theme. Table 2 provides a summary of which individ-
ual papers contribute to the four meta-themes and indicates
coverage. In the following, we detail descriptions of each
meta-theme and provide one or more quotes from contribu-
ting articles for illustrative purposes.
Short-term benefits
In the acute and early phase, patients described themselves
as particularly affected by severe symptoms. Psychotic states,
such as paranoia, mental chaos, and extreme fear, were per-
ceived as terrifying and made patients highly motivated to
reduce the burden of these symptoms. Antipsychotic medi-
cation was, particularly when reflected on retrospectively,
seen as efficient in reducing active psychosis symptoms in
the acute phase, but also in preventing relapse and re-hospi-
talization. Achieving functional recovery in the later course,
were by many seen as dependent on first reducing psychosis
symptoms. Thus, the threshold to commit to short-term
antipsychotic treatment was lower than when compared to
long-term use.
I’m very satisfied with the treatment I received. I got a lot of
help. I felt very safe on the ward. I trusted NN (psychiatrist).
She was fantastic … all the staff was actually like that… . I was
difficult to deal with, I must admit, I wasn’t a very easy patient.
I wasn’t violent, but I refused everything and initially I didn’t
want to take any medicine. Nevertheless, they were able to
convince me. I decided to use my antipsychotic medication for
one or perhaps two years, then I thought I would be able to
sustain myself without it. I will adhere to my doctor’s
recommendation (Yeisen, Bjornestad, Joa, Johannessen, &
Opjordsmoen, 2017)
Adverse effects and coping processes
Antipsychotic treatment was not seen as unconditionally
good. Finding an expedient drug and optimal dosage was
seen as a struggle to find a balance between positive effects
and unwanted side effects. The vast majority of studies
Table 2. Number and coverage.
Meta-theme Contributing papers Number Coverage
Short term benefits Bjornestad, Davidson et al. (2017a); Bjornestad, ten Velden Hegelstad
(2017); B€ulow, Andersson, Denhov, & Topor (2016), Carrick et al.
(2004); Chang et al. (2013); Das et al. (2014); Gault et al. (2013);
Gee et al. (2003); Geyt et al. (2017); Gray & Deane (2016), Hagen
et al. (2010); Hui et al. (2016); Lorem et al. (2014); Lloyd et al.
(2017); Morant et al. (2017); Morrison et al. (2015); Murphy et al.
(2015); Phillips & McCann (2007); Rogers et al. (1998); Svedberg
et al. (2003); Tranulis et al. (2011); Usher (2001); Vedana & Miasso
(2014); Yeisen et al. (2017)
23 Typical (72%)
Adverse effects and coping processes Bjornestad, Davidson et al. (2017); Bjornestad, ten Velden Hegelstad,
et al. (2017); B€ulow et al. (2016), Carrick (2004); Cocoman & Casey
(2018), Das et al. (2014); Gault et al. (2013); Gee et al. (2003); Geyt
et al. (2017); Gray & Deane (2016), Hagen et al. (2010); Lorem
et al. (2014); Lloyd et al. (2017); McCann & Clark (2004); Morant
et al. (2017); Morrison et (2015); Murphy et al. (2015); Phillips &
McCann (2007); Pyne et al.(2006); Rogers et al. (1998, 2003);
Stewart et al. (2010); Svedberg et al. (2003); Tranulis et al. (2011);
Usher (2001, Usher et al. (2013); Vandyk & Baker (2012); Vedana &
Miasso (2014); Yeisen et al.(2017); Zarea et al. (2016)
30 General (94%)
Surrender and autonomy Bjornestad, Davidson et al. (2017); B€ulow et al. (2016), Carrick et al.
(2004); Das et al.(2014); Gault et al. (2013); Geyt et al. (2017); Gray
& Deane (2016), Hagen et al. (2010); Hui et al. (2016); Lorem et al.
(2014); Lloyd et al. (2017); McCann & Clark (2004); Morant et al.
(2017); Morrison et al. (2015); Murphy et al. (2015); Phillips &
McCann (2007); Pyne et al. (2006); Rogers et al. (1998, 2003);
Stewart et al. (2010); Svedberg et al. (2003); Tranulis et al. (2011);
Usher (2001); Usher et al. (2013); Vandyk & Baker (2012); Vedana &
Miasso (2014); Yeisen et al. (2017); Zarea et al. (2016)
27 General (84%)
Long-term compromise of func-
tional recovery
Bjornestad, Davidson et al. (2017); Bjornestad, ten Velden Hegelstad,
et al. (2017); B€ulow et al. (2016), Cocoman & Casey (2018), Gee
et al. (2003); Geyt et al. (2017); Gray & Deane (2016), Hagen et al.
(2010); Hui et al. (2016); Lorem et al. (2014); Lloyd et al. (2017);
McCann & Clark (2004); Morant et al. (2017); Morrison et al. (2015);
Murphy et al. (2015); Pyne et al. (2006); Rogers et al. (1998);
Svedberg et al. (2003); Tranulis et al. (2011); Usher (2001); Usher
et al. (2013); Vedana & Miasso (2014); Zarea et al. (2016)
23 Typical (72%)
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described serious side effects. Reducing acute phase psych-
otic symptoms was mostly perceived to outweigh side
effects. During this stage, side effects were not perceived as
particularly destructive. However, when psychotic symptoms
abated, most patients found side effects exceedingly detri-
mental to their mental health and well-being. The signifi-
cance of these experiences was also emphasized in the
article titles in which long-term treatment was described in
terms such as “the least worst option” (Morant, Azam,
Johnson, & Moncrieff, 2017) and “the greater of two evils?”
(Hagen, Nixon, & Peters, 2010), and on-going use was
dependent on positive effects outweighing negative ones.
This drug has caused me a lot of evil, but I need it. It helps in
daily life. But there’s the side effect too, which bothers in daily
life as well (Vedana & Miasso, 2014)
The first time after taking it I couldn’t get up for 12 h. Now
2–4 h after taking it I can get up but I can’t get out of bed. It
makes me dark under my eyes. It makes me feel weak for
hours. I have somehow to get used to it (Gray & Deane, 2016)
Side effects perceived to cause functional decline, such as
reduced mental capacity and sedation, were seen as the
most compromising. Sexual dysfunction and weight gain
were emphasized in some papers. Patients described a
strong association between side effects limiting daily func-
tioning and non-adherence to antipsychotic drugs, often
against medical recommendations. The following quote
illustrates the disruptive severity of the side-effects to the
person’s achievement of his or her own goals.
The medication makes me put on weight actually, reduces my
motivation, changes other people’s attitudes towards me for the
worse, makes me feel depressed, sometimes I’m restless,
sometimes has a negative effect on my day to day living. Well
just that it makes me so physically disabled, so it reduces my
ability to function normally (Morant et al., 2017)
Surrender and autonomy
Communication early in the course of treatment were often
described from the patient perspective as a process of sur-
rendering, in which patients felt compelled to trust profes-
sional judgment and recommendations, including treatment
with antipsychotic medication. Surrendering was a highly
stressful process which required patients to develop a degree
of trust in the professional person’s being knowledgeable
and (at least) benign. Particularly, in cases of severe para-
noia and lessened insight, trust was hard to accomplish.
This often led to poor adherence or forced anti-
psychotic treatment.
So I was compliant with medication throughout my
hospitalization… . Still sceptical, I think … when you’re in the
hospital, it’s best to take your medication. You tend to get out
faster [laughter] if you do that (Tranulis, Goff, Henderson, &
Freudenreich, 2011)
Most patients perceived communication about anti-
psychotic treatment to be primarily a one-way interaction in
the short-term perspective. They rarely felt involved in treat-
ment decisions, and often had unanswered questions con-
cerning the adverse effects and treatment rationale. This
type of communication was experienced as a disregard of
personal treatment preferences, a lack of trust, and ultim-
ately an invalidation of the personhood of the patient who
struggled with psychotic symptoms. Such a perceived imbal-
ance often led to poor collaboration with treatment pro-
viders, feelings of powerlessness and resignation, and
termination of antipsychotic treatment. Furthermore, many
patients perceived professionals as applying sanctions when
they did not submit to the proposed treatment regime. Such
a use of power was experienced as particularly disturbing.
The following two quotes illustrate this tension between sur-
render, information, and collaboration.
At the end of the day it should be an individual’s choice what
they put into their body and I’m making a choice and I mean,
whether that choice is good or bad? But if you were given more
support to make the choices, then they’d probably be less
disastrous because you wouldn’t just be left on your own doing
it by your own means (Geyt, Awenat, Tai, & Haddock, 2017)
He told me that [unless I took the medication] I would never
be able to go to a normal school … and that I would never be
able to finish high school normally. And that I would never
graduate. And that I needed to get used to the idea that I would
be on medication for the rest of my life … that’s what he
actually told me (Hagen, Nixon, & Peters, 2010)
During the early stages, when patients suffered from cog-
nitive impairments and florid symptoms, they saw that it
was necessary for professionals to take sufficient time to
provide, and often repeat, important information. Shortly
after the acute phase – which for many patients involved
reduced psychotic symptoms and improved functioning –
patients emphasized that was pivotal to receive thorough
information about the biology of psychosis, effects and side
effects of antipsychotic medications, and the expected dur-
ation of use, all put forward in honest and understandable,
everyday language.
Also, in the longer term, patients saw it as essential that
communication was reciprocal, respectful, and involved a
high degree of user involvement both in treatment planning
and treatment delivery. Obtaining proper information, either
from the treatment provider or from personal reading, and
thus becoming knowledgeable about one’s own condition
and process, seemed important when moving from the
short-term horizon to thinking about living with the chal-
lenges over a longer term perspective. Moreover, patients
preferred professionals to view recovery as an individual
matter and to appreciate that antipsychotics were one of
many tools and not necessarily the main ingredient in
recovery. A perceived disproportionate or exclusive focus on
antipsychotic drugs was described as being in conflict with
participants’ ideas of improving as a social process, and
often resulted in resistance and non-adherence.
I think therapy was beneficial. Not so much the drugs. The
overly vast focus on drugs made me angry. My problems were
not about that. What worked was when I told my therapist how
I was doing, and he managed to tell me in another way why I
felt that way… . I think my Community Psychiatric Nurse takes
on board what I say she’s quite good, I can like test the waters
with her and then we will think about it and not just on one
single answer but look for a variety of avenues to follow
(Bjornestad, Davidson, et al., 2017)
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Other information sources, such as the Internet, social
media, and peers, augmented the dialogue between patients
and professionals. Gaining knowledge, comparing drug
effects, and learning from others with first-hand experience
of antipsychotic treatment were commonly used strategies
in moving from an initial surrender to authority to forming
an autonomous opinion on the process, with an increasing
sense of personal agency as a result. Patients regularly used
this information to challenge expert decisions and negotiate
treatment choices.
See we talk to each other and I know from a few of them in
here what they are taking so I learn from them. We know by
the colors and we know what are good ones and also the ones
that don’t help us much. The doctors they try a few and we
know from speaking to each other in here which ones we take
that help the most. So we learn from each other and compare
how the tablets work. It’s easy see when someone changes
tablets we can see how they behave and ask what they got to
help (Stewart, Anthony, & Chesson, 2010)
Long-term compromise of functional recovery
Long-term antipsychotic use was often perceived to disturb
individual efforts and the person’s sense of agency in over-
coming psychosis. Both these aspects were assessed as neces-
sary to enable the transition from being in need of care to
reaching functioning levels necessary for satisfactory partici-
pation in society. Medication made it difficult to parse out
the improvement resulting from the person’s decisions and
actions – as opposed to the drugs – and thereby reduced
the perceived impact of individual efforts. Long-term use of
antipsychotic medication also gave patients a feeling of
being stigmatized and deviant, and hence not suitable for
social inclusion and citizenship. The following quote illus-
trates this theme.
When you go out it’s like advertising you have a mental illness,
so the side effects draw attention to the fact that you have a
mental illness. And even though you might be quite well
mentally, the side effects stigmatize you… you can’t even go
over to your sister’s place and go out into the yard without the
neighbors thinking she’s got someone there who is mentally
ill… you know your legs are going up and down all the time
and they think you’re a lunatic. It’s like wearing a sign on your
forehead (Usher, 2001)
Long-term use was seen as a balancing act between anxi-
eties about relapse, which worked as a reminder not to quit
medications, and anxieties about irreparable bodily damage
caused by the drugs, which was an incentive to terminate
use. Another motivation for continued use was fear-based
statements from professionals, including warnings about the
dire consequences of decreasing or terminating anti-
psychotic treatment. This tug of war was perceived by many
as a drug labyrinth with no possibilities for escape, which
again gave rise to a sense of inadequacy, emotional flatten-
ing and fear. The following two quotes illustrate this theme.
It was like the lesser of two evils… . You can be scared and
paranoid or you can have no saliva. I was going to take the no
saliva but… it was trial and error… I’m glad I got to the
stage…where I actually feel like they are working (Murphy
et al., 2015)
When I told him again for the third time that I was trying to
get off these drugs, all he could do was get mad at me. He
started ranting on about how symptoms would come back 10%
worse every time I stopped taking the medication. It was crazy,
and I was thinking “so every time you put me on the
medications so that I can’t feel anything, I’m going to get more
and more psychotic every time I finally get the courage to take
myself off them? (Hagen et al., 2010)
Conversely, for those with a more positive perception of
long-term use, it was essential to adapt use to everyday set-
tings, including work, parenting, and social life. Here,
reducing side effects through either dose-reduction or
through manipulating the time points for when the hardest
side effects were hitting – e.g. taking drugs in the middle of
the night instead of in the morning – were seen as crucial.
This usually involved some experimenting alone and in dia-
logue with professionals. The following quote illustrates this
process of personalization and negotiating degrees of free-
dom in order to achieve autonomy.
They are so strong so I set the alarm clock to half past three in
the morning, take the medicine and go back to sleep. Then I
wake up at half past seven and get up. If I had taken them at
half past seven, as prescribed, my work mates would think that
I was drunk when I came to work (B€ulow, Andersson, Denhov,
& Topor, 2016)
A proposed model of processes between meta-themes
Figure 2 presents a first-person experiential model of using
antipsychotic medication based on the meta-analysis of 32
included studies. The model proposes meta-thematic con-
tent organized on a time continuum, including the experi-
ence level of the person suffering from psychosis, illness
phases, and power dynamics. The developmental process
from being a novice user of mental health services in
general, and antipsychotic medication in particular, to
becoming an experienced patient, was pivotal. Meanings
attached to antipsychotic medications were significantly dif-
ferent when the horizon was the short-term acute situation
rather than the long-term recovery-oriented perspective.
While the need to be helped by medication and experts to
silence chaos and terror overshadowed other needs when
inexperienced patients went through acute phases, a per-
sonal cost–benefit analysis and a risk management analysis
became central at later stages. Hence, evolving knowledge,
value-based opinions, and need for a sense of personal
responsibility seems to constitute an overarching process.
Developing autonomy with regard to one’s own suffering
and interactions with mental health services appeared to be
an organizing principle that followed a similar path.
Achieving autonomy seemed to emerge from increased
knowledge via information from professionals, peers and,
importantly, one’s own explorations and experimentations.
Becoming knowledgeable helped the person to develop
autonomy in the face of his or her initial sense of surrender,
and subsequently to establish a sense of personhood. This
sense of self (Davidson & Strauss, 1992) has long been
argued to be central to recovery processes. From the per-
spective of becoming autonomous, cost–benefit analyses and
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risk evaluations appeared to change throughout the course
of suffering. Side effects that were acceptable for the short
term seemed autonomously evaluated vis-a-vis the long-
term goals and values of the individual. Risk negotiated
from within oneself yielded different results than when the
doctor was responsible for the risk matrix. For illustration,
in the included study by Geyt et al. (2017), one quote states
that the rational choice from the doctor’s perspective is
understandably to tolerate as little risk on the patients’
behalf as possible, whereas when a patient is considering




Study findings shed light on how the prescribing and use of
antipsychotic drugs should be tailored to patients’ individual
symptoms, functioning, and experience level. The meta-ana-
lytic results echo previous research findings suggesting anti-
psychotic medication as an efficient treatment of psychosis
during the acute phase and short-term (Leucht et al., 2017;
Sohler et al., 2016). A reported challenge in psychosis is that
a substantial sub-group of patients stop taking antipsychotic
drugs before recommendations indicate (Kane et al., 2013).
Rather than assuming that this decision is due to denial or
a lack of insight, as is often suggested, it should be explored
whether such decision results from an autonomous process
in which the more experienced patient needs to negotiate
level of perceived freedom vis-a-vis his or her own psychotic
experiences. In line with other research on user experiences,
it seems pivotal for treatment to be efficient to early identify
these types of discrepancies in professionals’ and service
users’ views (Davidson, 1992; Russo, 2018). Our results
underscore that patients should be continuously informed
about antipsychotic treatment by many sources. Results sup-
port that antipsychotic drugs are best presented as a part of
a comprehensive treatment package – including, for
example, psychotherapy, family therapy, and/or rehabilita-
tion supports – and not as the exclusive or primary tool
for recovery.
Further, information appears to best facilitate successful
use when delivered in a manner that supports and sustains
the person’s concerns with his or her autonomy and indi-
vidual efforts. A straightforward and honest use of everyday
language can promote a collaborative framework (Dixon,
Holoshitz, & Nossel, 2016; Thomas, 2015), and a respectful
tone was considered a powerful remedy for early discontinu-
ation. Patients described preferring communications to be
especially clear and to include repetition of important
aspects over time.
Over the longer-term, treatment professionals should be
sensitive to changes in patients’ needs and treatment prefer-
ences. In particular, introducing functional and social
aspects into the dialog, aspects previously shown critical for
remission and recovery (Bjornestad, Joa, et al., 2016;
Bjornestad, ten Velden Hegelstad, et al., 2017; Davidson
et al., 2001; Marder & Galderisi, 2017), seems crucial for a
fruitful dialogue to develop and to promote a successful
long-term outcome. Here, a system-wide implementation of
safeguards and checkpoints to monitor the quality and
impact of patients’ experiences related to treatment, includ-
ing antipsychotic drugs, seems called for. Findings advocate,
in addition to evaluating the severity of symptoms of psych-
osis in themselves, contexts of patient experience level,
patient autonomy processes, patient values and risk prefer-
ences, and patient knowledge and knowledge needs, need to
be included in the clinical conversation about medica-
tion use.
Figure 2. A first-person experimental model of anti-psychotic medication use.
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Limitations
The qualitative meta-analysis is relatively comprehensive
with regard to the number of sampled articles, but might be
limited by the variability between the included studies. By
which method and design first-person experiences with
anti-psychotic medication are studied differs in the sample.
Thus, concepts such as degree of coverage for individual
meta-themes should be interpreted with caution.
Programmes of qualitative studies in which a field agreeing
on a set of interview schedules and methods to use for a
given research question for a particular period in time
would be a potential development. Another potential limita-
tion is that the data material in this meta-analysis includes
three articles reported by some of the present authors (J. B.,
L. D., and M. V.), suggesting a risk of bias. To overcome
this limitation we have composed a group of researchers in
which half had not taken part in previous studies, and
established rigorous reflexivity processes as described in the
methods section, to ensure stringency. The critical auditor
(A. H.) in this study was not involved in the research proj-
ects that constitute our data material and is, therefore, inde-
pendent. All authors have a background as clinical
psychologists, which may have contributed to an important
analytical distance in carrying out the study. In so doing,
however, the research team does not include people with
first-hand experiences with antipsychotic medication or the
groups of professionals (medical doctors and nurses).
Coverage (see Table 2) should also be interpreted with cau-
tion, as lack of coverage can be due to slight differences in
scope and interview schedules in heterogeneous individual
studies. Finally, grey literature was not included. While this
allowed for strict and transparent inclusion criteria and
legitimacy as the peer-review processes in established
scientific journals ensure a basic level of quality, important
first-person descriptions may have been overlooked in this
process. We recommend that future studies systematize the
grey literature of people’s experiences of using antipsychotic
medication. This limitation will in this study typically raise
the risk of reporting bias, implying that the included studies
represent selective research dissemination.
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